Investing.com -- Maze Therapeutics, a clinical-stage biopharmaceutical company, launched its initial public offering (IPO) today, with shares starting to trade at $16.12. The company priced 8,750,000 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback